This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Wagner J , Kline CL , Ralff MD , Lev A , Lulla A , Zhou L , Olson GL , Nallaganchu BR , Benes CH , Allen JE , Prabhu VV , Stogniew M , Oster W , El-Deiry WS
Preclinical evaluation of the imipridone family, analogues of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212
Cell Cycle. 2017 Oct 02;16(19) :1790-1799
PMID: 28489985 PMCID: PMC5628644 URL: https://www.ncbi.nlm.nih.gov/pubmed/28489985
AbstractAnti-cancer small molecule ONC201 upregulates the integrated stress response (ISR) and acts as a dual inactivator of Akt/ERK, leading to TRAIL gene activation. ONC201 is under investigation in multiple clinical trials to treat patients with cancer. Given the unique imipridone core chemical structure of ONC201, we synthesized a series of analogues to identify additional compounds with distinct therapeutic properties. Several imipridones with a broad range of in vitro potencies were identified in an exploration of chemical derivatives. Based on in vitro potency in human cancer cell lines and lack of toxicity to normal human fibroblasts, imipridones ONC206 and ONC212 were prioritized for further study. Both analogues inhibited colony formation, and induced apoptosis and downstream signaling that involves the integrated stress response and Akt/ERK, similar to ONC201. Compared to ONC201, ONC206 demonstrated improved inhibition of cell migration while ONC212 exhibited rapid kinetics of activity. ONC212 was further tested in >1000 human cancer cell lines in vitro and evaluated for safety and anti-tumor efficacy in vivo. ONC212 exhibited broad-spectrum efficacy at nanomolar concentrations across solid tumors and hematological malignancies. Skin cancer emerged as a tumor type with improved efficacy relative to ONC201. Orally administered ONC212 displayed potent anti-tumor effects in vivo, a broad therapeutic window and a favorable PK profile. ONC212 was efficacious in vivo in BRAF V600E melanoma models that are less sensitive to ONC201. Based on these findings, ONC212 warrants further development as a drug candidate. It is clear that therapeutic utility extends beyond ONC201 to include additional imipridones.
Notes1551-4005 Wagner, Jessica Kline, Christina Leah Ralff, Marie D Lev, Avital Lulla, Amriti Zhou, Lanlan Olson, Gary L Nallaganchu, Bhaskara Rao Benes, Cyril H Allen, Joshua E Prabhu, Varun V Stogniew, Martin Oster, Wolfgang El-Deiry, Wafik S Journal Article United States Cell Cycle. 2017 May 10:0. doi: 10.1080/15384101.2017.1325046.